Skip to main content

Table 3 Safety and tolerance within the first 7 days following treatment initiation

From: Comparison of hydroxychloroquine, lopinavir/ritonavir, and standard of care in critically ill patients with SARS-CoV-2 pneumonia: an opportunistic retrospective analysis

Tolerance issues Total
n = 80
Standard of care
n = 22
Lopinavir/ritonavir
n = 20
Hydroxy-chloroquine
n = 38
p value
Neutropenia, n (%) 1 (1) 0 (0) 1 (5) 0 (0) 0.219
Anemia, n (%) 7 (9) 2 (9) 2 (10) 3 (8) 0.962
Thrombocytopenia, n (%) 10 (13) 2 (9) 3 (15) 5 (13) 0.834
Increased aspartate aminotransferase > 5 N, n (%) 20 (25) 6 (27) 7 (35) 7 (18) 0.367
Increased alanine aminotransferase > 5 N, n (%) 14 (18) 3 (14) 3 (15) 8 (21) 0.724
Acute renal failure KDIGO ≥ 2, n (%) 40 (50) 12 (55) 12 (60) 16 (42) 0.381
Prolonged QT interval*, n (%) 1 (1) 0 (0) 0 (0) 1 (3) 0.571
  1. Categorical variables are expressed as absolute value (%). p values are given for the comparison between groups of treatment
  2. KDIGO Kidney disease improving global outcome
  3. *QT interval is prolonged when > 450 ms in men and > 470 ms in women